BAKER BROS. ADVISORS LP Q2 2018 Filing
Filed August 14, 2018
Portfolio Value
$13.3B
Holdings
119
Report Date
Q2 2018
Filing Type
13F-HR
All Holdings (119 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 101 | I9DNArbutus Biopharma Corporation | 180,582 | $1.3B | 9.90% | |
| 102 | CRBPEURCorbus Pharmaceuticals Holdings, Inc. | 247,450 | $1.3B | 9.39% | |
| 103 | SELBUSDSelecta Biosciences, Inc. | 93,750 | $1.2B | 9.33% | |
| 104 | ADAPYAdaptimmune Therapeutics plc | 100,000 | $1.2B | 8.92% | |
| 105 | —Sunesis Pharmaceuticals, Inc. | 556,665 | $1.2B | 8.87% | |
| 106 | DVAXDynavax Technologies Corporation | 75,000 | $1.1B | 8.60% | |
| 107 | INFIQInfinity Pharmaceuticals, Inc. | 580,400 | $1.1B | 8.33% | |
| 108 | —T2 Biosystems, Inc. | 100,000 | $774.0M | 5.82% | |
| 109 | JNCEEURJounce Therapeutics, Inc. | 100,000 | $766.0M | 5.76% | |
| 110 | —Proteon Therapeutics, Inc. | 298,591 | $732.0M | 5.50% | |
| 111 | —Ritter Pharmaceuticals, Inc. | 279,999 | $720.0M | 5.41% | |
| 112 | —Stemline Therapeutics, Inc. | 44,524 | $715.0M | 5.37% | |
| 113 | —Affimed N.V. | 400,000 | $660.0M | 4.96% | |
| 114 | —BioDelivery Sciences International, Inc. | 210,021 | $620.0M | 4.66% | |
| 115 | FLGTFulgent Genetics, Inc. | 125,000 | $518.0M | 3.89% | |
| 116 | —Molecular Templates, Inc. | 72,412 | $379.0M | 2.85% | |
| 117 | —Akari Therapeutics, Plc | 58,770 | $115.0M | 0.86% | |
| 118 | BGMS 6 PERPCyclacel Pharmaceuticals, Inc. | 13,253 | $89.0M | 0.67% | |
| 119 | —BioTime, Inc. | 20,084 | $1.0M | 0.01% |
PreviousPage 2 of 2